Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data
highlights from six presentations showcasing technology advances in
the company’s antibody-drug conjugate (ADC) platform and an
immuno-oncology program at the American Association for Cancer
Research (AACR) Annual Meeting 2019 being held March 29-April 3,
2019 in Atlanta.
“Our expertise in empowered-antibody innovation drives a
substantial, advancing pipeline of clinical and preclinical
programs, including both ADCs and immuno-oncology agents,” said
Dennis Benjamin, Ph.D., Senior Vice President of Research at
Seattle Genetics. “For example, the research presented in an oral
presentation at AACR illustrates why we believe SGN-CD228A is well
positioned for IND-enabling studies and a phase 1 study is planned
in multiple tumor types. The program features a novel ADC targeted
to CD228, which is highly expressed in several types of cancer. The
ADC employs our proprietary auristatin technology and has shown
antitumor activity in vitro and in vivo.”
Abstracts can be found at www.aacr.org and include the
following:
SGN-CD228A: A novel humanized anti-CD228 antibody-drug
conjugate for the treatment of solid tumors (Abstract
#2688)Date: Monday, April 1, 2019Time: 3:00 p.m.
– 5:00 p.m. ET, Oral Presentation at 3:20 p.m. ET, Room B401
The cell-surface protein CD228 is highly expressed in several
types of cancer, including melanoma, mesothelioma, non-small cell
lung (NSCLC), breast, colorectal and pancreatic cancers. SGN-CD228A
is an auristatin-based ADC targeted to CD228. The preliminary data
show antitumor activity in preclinical evaluations in melanoma,
NSCLC and triple negative breast cancer.
Antibody-drug conjugates of NAMPT inhibitors: Discovery,
optimization and preclinical characterization (Abstract
#983)Date: Monday, April 1, 2019Time: 8:00 a.m. –
12:00 p.m. ET, Poster Session
At the AACR Annual Meeting 2018, data were presented showing
ADCs with a proprietary NAMPT inhibitor payload have a unique
mechanism of action and an encouraging therapeutic window. This
poster presentation will highlight preclinical results from the
optimization of the novel payload and linker strategy, and
application to ADCs, which data indicate drive tumor regression in
models of Hodgkin lymphoma, non-Hodgkin lymphoma and acute myeloid
leukemia (AML). The targeted delivery approach using ADCs
demonstrates an improved safety profile relative to previously
described unconjugated NAMPT inhibitors.
TIGIT directed human antibody modulates T-regulatory and
effector cell function (Abstract #4986)Date: Wednesday,
April 3, 2019Time: 8:00 a.m. – 12:00 p.m. ET, Poster
Session
The immune checkpoint receptor TIGIT negatively regulates the
function of adaptive (T cell) and innate (natural killer or NK)
cells and blockade of TIGIT signaling may elicit an antitumor
immune response. Preclinical data from an antibody program
targeting TIGIT demonstrate in vitro activation of T cells and
antitumor activity in several syngenic models.
Development of patient-derived acute myeloid leukemia
xenograft models (Abstract #1062)Date: Monday, April 1,
2019Time: 8:00 a.m. – 12:00 p.m. ET, Poster Session
This poster presentation is focused on successfully establishing
a collection of AML xenograft models that more accurately reflect
the antigen expression and molecular genetics of AML patients.
These models will enable a more precise assessment of therapeutic
candidates in preclinical testing.
Functional cell surface proteomics of acute myeloid leukemia
enables predictive modeling of antibody-drug conjugate cytotoxicity
(Abstract #4546)Date: Wednesday, April 3,
2019Time: 8:00 a.m. – 12:00 p.m. ET, Poster Session
This poster profiles the cell surface landscape of more than 100
primary hematologic samples comprising leukemic blasts from
patients treated in the Beat AML research consortium along with
normal bone marrow cells from healthy donors. Based on cell surface
proteomics, a number of highly expressed antigens were identified
and targeted ADCs were evaluated on a panel of AML cell lines.
CD317 was determined as a novel target for AML.
Tisotumab vedotin induces anti-tumor activity through
MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in
vitro (Abstract #221)Date: Sunday, March 31,
2019Time: 1:00 p.m. – 5:00 p.m. ET, Poster Session
Tisotumab vedotin is an investigational ADC designed to target
Tissue Factor (TF) antigen on TF-expressing cell surfaces and
deliver the cell-killing agent monomethyl auristatin E (MMAE)
directly inside TF-expressing cells. The Tissue Factor antigen
target is overexpressed in the vast majority of patients with
cervical cancer and in many other solid tumors, including ovarian,
lung, pancreatic, colorectal and head and neck. This poster
presentation evaluates tisotumab vedotin’s antitumor activity
through several mechanisms, including immunogenic cell death,
bystander cytotoxicity, and antibody-dependent cellular
phagocytosis in vitro.
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global
biotechnology company that develops and commercializes
transformative therapies targeting cancer to make a meaningful
difference in people’s lives. ADCETRIS® (brentuximab vedotin)
utilizes the company’s industry-leading antibody-drug conjugate
(ADC) technology and is currently approved for the treatment of
multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company
has established a pipeline of novel targeted therapies at various
stages of clinical testing, including three in ongoing pivotal
trials for solid tumors. Enfortumab vedotin for metastatic
urothelial cancer and tisotumab vedotin for metastatic cervical
cancer utilize our proprietary ADC technology. Tucatinib, a small
molecule tyrosine kinase inhibitor, is in a pivotal trial for
HER2-positive metastatic breast cancer. In addition, we are
leveraging our expertise in empowered antibodies to build a
portfolio of proprietary immuno-oncology agents in clinical trials
targeting hematologic malignancies and solid tumors. The company is
headquartered in Bothell, Washington, and has a European office in
Switzerland. For more information on our robust pipeline, visit
www.seattlegenetics.com and follow @SeattleGenetics on Twitter.
Forward-Looking Statements
Certain of the statements made in this press release are
forward-looking, such as those, among others, relating to the
possible utility or application of the Company’s technologies to
develop therapeutic agents, therapeutic potential of
investigational agents, and future development activities including
clinical trials. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
difficulty and uncertainty of pharmaceutical product development,
including the risks that Seattle Genetics may experience delays in
its planned clinical trial initiations or otherwise experience
failures or setbacks in its preclinical and clinical development
programs due to the potential lack of efficacy or risk of adverse
events as Seattle Genetics’ product candidates advance in
development or other factors. More information about the risks and
uncertainties faced by Seattle Genetics is contained under the
caption “Risk Factors” included in the company’s Annual Report on
Form 10-K for the year ended December 31, 2018 filed with the
Securities and Exchange Commission. Seattle Genetics disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190327005038/en/
Media:Monique Greer(425) 527-4641mgreer@seagen.com
Investors:Peggy Pinkston(425) 527-4160ppinkston@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024